More News! GSK’s Pipeline Shakeup, Bayer’s Failure & an EU Investigation

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

Oleksii G
  • Bayer’s ADC for mesothelioma failed in Phase II, collaterally denting the stocks of its partners MorphoSys and ImmunoGen
  • Themis has kicked off a Phase II study of its Chikungunya vaccine in Puerto Rico, where the disease is endemic

Brian Lasenby

  • Do presubmission meetings with the EMA open the door for drugmakers to influence MAA decisions? The EU is investigating.
  • Emma Walmsley, GSK’s CEO, is making big moves to overhaul the pharma’s pipeline

Images from Brian Lasenby, Nirun Thuwasin, Marco Diaz Segura, Oleksii G, Janossy Gergely, Vladimir Wrangel / shutterstock.com

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.